Introduction : Anaemia is one of the most common complications of Chronic Kidney Disease (CKD) and significantly impairs the quality of life of patients undergoing chronic haemodialysis. The aim of this study was to describe the clinical, therapeutic, and evolutionary aspects of anaemia in chronic haemodialysis patients at Fousseyni Daou Hospital in Kayes, Mali. Methodology: We conducted a prospective, descriptive cohort study lasting four months, from 1 June to 1 October 2025, at the haemodialysis centre of the Fousseyni Daou Hospital in Kayes. Patients who had been on chronic haemodialysis for at least three months and had a haemoglobin level below 11 g/dl on their blood count were included. Results : During the study period, 70 patients out of 117 participants were selected, including 39 women (55.7%) and 31 men (44.3%). The average age was 46.97 years ± 14.20. The average duration of haemodialysis was 21 months. The mean haemoglobin level was 7.91 g/dl ± 1.47. Twenty-seven patients (38.6%) had a haemoglobin level below 8 g/dl. The respective means for ferritin and saturation coefficient were 1044.60 ng/ml ± 477.98 and 31.10% ± 7.33%. Ferritin levels were below 500 ng/ml in 8 patients (11.4%), and the saturation coefficient was below 30% in 22 patients (31.4%). Blood transfusions were performed in 90% of patients. Intravenous iron supplementation was performed in 62 patients (88.6%). Erythropoietin (EPO) was administered occasionally in 44 patients (62.9%). Eleven patients (15.7%) received EPO at the optimal therapeutic dose (loading and maintenance dose) per week. Among the 11 patients who received optimal EPO treatment, 8 achieved a mean target haemoglobin level of 11 g/dl during the study period. Conclusion: Managing anaemia in haemodialysis patients in our context remains a real challenge. Optimising EPO treatment is still hampered by limiting factors, particularly economic ones. It must be integrated into a sound national policy for care provided by the competent health authorities.
van Haalen, H., Jackson, J., Spinowitz, B., Milligan, G. and Moon, R. (2020) Impact of Chronic Kidney Disease and Anemia on Health-Related Quality of Life and Work Productivity: Analysis of Multinational Real-World Data. BMC Nephrology , 21, Article No. 88. https://doi.org/10.1186/s12882-020-01746-4
Lamerato, L., James, G., van Haalen, H., Hedman, K., Sloand, J.A., Tang, A., et al . (2022) Epidemiology and Outcomes in Patients with Anemia of CKD Not on Dialysis from a Large US Healthcare System Database: A Retrospective Observational Study. BMC Nephrology , 23, Article No. 166. https://doi.org/10.1186/s12882-022-02778-8
Al-Ahmad, A., Rand, W.M., Manjunath, G., Konstam, M.A., Salem, D.N., Levey, A.S., et al . (2001) Reduced Kidney Function and Anemia as Risk Factors for Mortality in Patients with Left Ventricular Dysfunction. Journal of the American College of Cardiology , 38, 955-962. https://doi.org/10.1016/s0735-1097(01)01470-x
Thorp, M.L., Johnson, E.S., Yang, X., Petrik, A.F., Platt, R. and Smith, D.H. (2009) Effect of Anaemia on Mortality, Cardiovascular Hospitalizations and End‐Stage Renal Disease among Patients with Chronic Kidney Disease. Nephrology , 14, 240-246. https://doi.org/10.1111/j.1440-1797.2008.01065.x
Babitt, J.L. and Lin, H.Y. (2012) Mechanisms of Anemia in CKD. Journal of the American Society of Nephrology , 23, 1631-1634. https://doi.org/10.1681/asn.2011111078
Elliott, J., Mishler, D. and Agarwal, R. (2009) Hyporesponsiveness to Erythropoietin: Causes and Management. Advances in Chronic Kidney Disease , 16, 94-100. https://doi.org/10.1053/j.ackd.2008.12.004
Wong, M.M.Y., Tu, C., Li, Y., Perlman, R.L., Pecoits-Filho, R., Lopes, A.A., et al . (2020) Anemia and Iron Deficiency among Chronic Kidney Disease Stages 3-5ND Patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: Often Unmeasured, Variably Treated. Clinical Kidney Journal , 13, 613-624. https://doi.org/10.1093/ckj/sfz091
Minutolo, R., Grandaliano, G., Di Rienzo, P., Snijder, R., Degli Esposti, L., Perrone, V., et al . (2023) Prevalence, Incidence, and Treatment of Anaemia in Patients with Non-Dialysis-Dependent Chronic Kidney Disease: Findings from a Retrospective Real-World Study in Italy. Journal of Nephrology , 36, 347-357. https://doi.org/10.1007/s40620-022-01475-x
Kimura, T., Snijder, R. and Nozaki, K. (2020) Diagnosis Patterns of CKD and Anemia in the Japanese Population. Kidney International Reports , 5, 694-705. https://doi.org/10.1016/j.ekir.2020.03.006
Cases-Amenos, A., Martinez-Castelao, A., Fort-Ros, J., Bonal-Bastons, J., Ruiz, M.P., et al . (2014) Prevalence of Anaemia and Its Clinical Management in Patients with Stages 3-5 Chronic Kidney Disease Not on Dialysis in Catalonia: MICENAS I Study. Nefrologia , 34, 189-198.
KDIGO Anemia Work Group (2012) KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney International , 2, 279-335.
Tounkara, A.A., Sériba Coulibaly, A.M., Coulibaly, N., Traoré, B. and Maïga, M.K. (2017) Gestion de l’Anémie des patients hémodialysés chroniques: Cas du Service de Néphrologie et d’hémodialyse du CHU du Point G au Mali. Pan African Medical Journal , 26, Article 167. https://doi.org/10.11604/pamj.2017.26.167.10861
Cinquième recensement général de la population et de l’habitat (RGPH). https://www.instat-mali.org/fr/publications/recensement-general-de-la-population-et-de-lhabitat-rgph
(2006) KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. American Journal of Kidney Diseases , 47, S11-145.
Taderegew, M.M., Wondie, A., Terefe, T.F., Tarekegn, T.T., GebreEyesus, F.A., Mengist, S.T., et al . (2023) Anemia and Its Predictors among Chronic Kidney Disease Patients in Sub-Saharan African Countries: A Systematic Review and Meta-Analysis. PLOS ONE , 18, e0280817. https://doi.org/10.1371/journal.pone.0280817
Kaze, F., Kengne, A., Mambap, A., Halle, M., Mbanya, D. and Ashuntantang, G. (2015) Anemia in Patients on Chronic Hemodialysis in Cameroon: Prevalence, Characteristics and Management in Low Resources Setting. African Health Sciences , 15, 253-260. https://doi.org/10.4314/ahs.v15i1.33
Locatelli, F., Bárány, P., Covic, A., De Francisco, A., Del Vecchio, L., Goldsmith, D., et al . (2013) Kidney Disease: Improving Global Outcomes Guidelines on Anaemia Management in Chronic Kidney Disease: A European Renal Best Practice Position Statement. Nephrology Dialysis Transplantation , 28, 1346-1359. https://doi.org/10.1093/ndt/gft033
Gilbertson, D.T., Monda, K.L., Bradbury, B.D. and Collins, A.J. (2013) RBC Transfusions among Hemodialysis Patients (1999-2010): Influence of Hemoglobin Concentrations Below 10 G/dl. American Journal of Kidney Diseases , 62, 919-928. https://doi.org/10.1053/j.ajkd.2013.05.004
Besarab, A., Reyes, C.M. and Hornberger, J. (2002) Meta-Analysis of Subcutaneous versus Intravenous Epoetin in Maintenance Treatment of Anemia in Hemodialysis Patients. American Journal of Kidney Diseases , 40, 439-446. https://doi.org/10.1053/ajkd.2002.34881
Diallo, D. (2009) Traitement de l’anémie chez les patients hémodialysés chronique, dans le service de néphrologie et d’hémodialyse du Point G. Thèse de Médecine, Université des Sciences, des Techniques et des Technologies de Bamako.
Pisoni, R.L., Bragg-Gresham, J.L., Young, E.W., Akizawa, T., Asano, Y., Locatelli, F., et al . (2004) Anemia Management and Outcomes from 12 Countries in the Dialysis Outcomes and Practice Patterns Study (Dopps). American Journal of Kidney Diseases , 44, 94-111. https://doi.org/10.1053/j.ajkd.2004.03.023
Haute Autorité de Santé (HAS) (2013) Anémie chez l’insuffisant rénal: Comment utiliser les agents stimulant l’érythropoïèse. https://www.has-sante.fr/upload/docs/application/pdf/2013-09/fs_bum_epo_v5.pdf
(2025) FDA Drug Safety Communication: Modified Dosing Recommendations to Improve the Safe Use of Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease.
Phrommintikul, A., Haas, S.J., Elsik, M. and Krum, H. (2007) Mortality and Target Haemoglobin Concentrations in Anaemic Patients with Chronic Kidney Disease Treated with Erythropoietin: A Meta-Analysis. The Lancet , 369, 381-388. https://doi.org/10.1016/s0140-6736(07)60194-9
Moura, A.F., Moitinho, J.A.O., da Luz, L.G., Suassuna, J.H.R. and Moura-Neto, J.A. (2023) Anemia in Dialysis Patients. In: Fadem, S.Z., Moura-Neto, J.A. and Golper, T.A., Eds., Complications in Dialysis , Springer International Publishing, 157-170. https://doi.org/10.1007/978-3-031-44557-6_6
Giancaspro, V., Nuzziello, M., Pallotta, G., Sacchetti, A. and Petrarulo, F. (2000) Intravenous Ascorbic Acid in Hemodialysis Patients with Functional Iron Deficiency: A Clinical Trial. Journal of Nephrology , 13, 444-449.
Chen, N., Hao, C., Liu, B., Lin, H., Wang, C., Xing, C., et al . (2019) Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. New England Journal of Medicine , 381, 1011-1022. https://doi.org/10.1056/nejmoa1901713
Nakanishi, T. and Kuragano, T. (2024) Growing Concerns about Using Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for the Treatment of Renal Anemia. Clinical Kidney Journal , 17, 1-10. https://doi.org/10.1093/ckj/sfae051